itus develops and acquires patented technologies for the purposes of patent monetization and patent assertion. the company currently has 8 patent portfolios in the areas of key based web conferencing encryption, encrypted cellular communications, nano field emission display (“nfed”), micro electro mechanical systems display (“mems”), j-channel window frame construction, vpn multicast communications, internet telephonic gateway, and enhanced auction technologies. itus’s management team has over 30 years of combined experience in patent monetization and patent assertion, and has generated in excess of $150 million patent licensing revenues
Company profile
Ticker
ANIX
Exchange
Website
CEO
Amit Kumar
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
COPYTELE INC, ITUS Corp
SEC CIK
Corporate docs
Subsidiaries
Anixa Diagnostics Corporation • Certainty Therapeutics, Inc. • CopyTele International Ltd. • CopyTele Marketing Inc. • ITUS Patent Acquisition Corporation • J-Channel Industries Corporation • Loyalty Conversion Systems Corporation • Secure Web Conference Corporation • Encrypted Cellular Communications Corporation • Auction Acceleration Corp. ...
IRS number
112622630
ANIX stock data
Latest filings (excl ownership)
8-K
Submission of Matters to a Vote of Security Holders
22 Mar 24
10-Q
2024 Q1
Quarterly report
12 Mar 24
DEF 14A
Definitive proxy
8 Feb 24
S-8
Registration of securities for employees
16 Jan 24
10-K
2023 FY
Annual report
16 Jan 24
8-K
Regulation FD Disclosure
7 Dec 23
10-Q
2023 Q3
Quarterly report
6 Sep 23
10-Q
2023 Q2
Quarterly report
14 Jun 23
8-K
Anixa Biosciences and Cleveland Clinic Present Positive Data for Phase 1 Study of Breast Cancer Vaccine
17 Apr 23
10-Q
2023 Q1
Quarterly report
16 Mar 23
Latest ownership filings
Financial summary
Quarter (USD) | Oct 23 | Jul 23 | Apr 23 | Jan 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Oct 23 | Oct 22 | Oct 21 | Oct 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 915.00 k | 915.00 k | 915.00 k | 915.00 k | 915.00 k | 915.00 k |
Cash burn (monthly) | 761.00 k | 953.75 k | 1.02 mm | 917.58 k | 656.33 k | 517.42 k |
Cash used (since last report) | 4.31 mm | 5.40 mm | 5.75 mm | 5.19 mm | 3.71 mm | 2.93 mm |
Cash remaining | -3.39 mm | -4.48 mm | -4.84 mm | -4.28 mm | -2.80 mm | -2.01 mm |
Runway (months of cash) | -4.5 | -4.7 | -4.8 | -4.7 | -4.3 | -3.9 |
Institutional ownership, Q3 2023
12.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 7 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 12.59 bn |
Total shares | 3.93 mm |
Total puts | 300.00 |
Total calls | 56.90 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 1.36 mm | $4.46 bn |
UBS UBS Group AG - Registered Shares | 604.44 k | $1.98 bn |
Mission Wealth Management | 501.17 k | $1.64 bn |
Geode Capital Management | 299.65 k | $980.11 mm |
Long Focus Capital Management | 165.70 k | $541.84 mm |
BLK Blackrock | 161.57 k | $528.32 mm |
STT State Street | 102.10 k | $333.87 mm |
BK Bank Of New York Mellon | 96.60 k | $315.87 mm |
Raymond James & Associates | 56.58 k | $185.02 mm |
NTRS Northern Trust | 53.44 k | $174.76 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
9 Apr 24 | Titterton Lewis H jr | Common Stock | Buy | Acquire P | No | No | 3.28 | 15,009 | 49.23 k | 838,037 |
15 Mar 24 | Kumar Amit | Common Stock | Buy | Acquire P | No | No | 3.22 | 30,000 | 96.60 k | 491,925 |
15 Mar 24 | Baskies Arnold M | Common Stock | Buy | Acquire P | No | No | 3.63 | 10,000 | 36.30 k | 110,000 |
12 Jan 24 | Titterton Lewis H jr | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.39 | 25,000 | 109.75 k | 25,000 |
12 Jan 24 | Kumar Amit | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.39 | 700,000 | 3.07 mm | 700,000 |
News
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
21 Mar 24
Recap: Anixa Biosciences Q1 Earnings
12 Mar 24
HC Wainwright & Co. Reiterates Buy on Anixa Biosciences, Maintains $12 Price Target
13 Feb 24
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
12 Feb 24
Anixa Biosciences Announces Japanese Patent On Ovarian Cancer Vaccine Technology
23 Jan 24
Press releases
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
18 Apr 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24
Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth
20 Mar 24
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
14 Mar 24